Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170781
Status:
COMPLETED
Last Update Posted:
2006-11-30
First Post:
2005-09-09
Brief Title:
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 1-Week Multi-Center Randomized Double-Blind Double-Dummy Active-Controlled Parallel Trial Comparing Lumiracoxib 400 mg Once Daily in Patients With Acute Flares of Gout Using Indomethacin 50 mg Three Times a Day
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout This is a multi-center double-blind randomized parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None